Myasthenia gravis is an autoimmune disease with impaired neuromuscular transmission. It is a chronic disease with impaired transmission at the neuromuscular junction. Antibodies to acetylcholine receptors are the main autoantibodies responsible for its pathogenesis, mainly producing antibodies to Ach receptors that block transmission at the neuromuscular junction, resulting in weakness of the eye muscles, swallowing muscles, respiratory muscles, and skeletal muscles of the limbs. In other words, the nerves that innervate muscle contraction cannot transmit “signal instructions” to the muscles normally due to the influence of various causes, so that the muscles lose their contraction function. The cause of this disease is systemic, but the affected muscles may have different clinical manifestations due to their focus. In adults with myasthenia gravis, the clinical manifestations are diverse, often starting with droopy eyelids, double vision, strabismus or complete inability to move the eyes; often accompanied by night sweats, the disease gradually involves the facial muscles, swallowing muscles, cervical muscles and limb muscles, and the symptoms of generalized muscle weakness such as shortness of breath and laziness, feeling sore and weak at the slightest activity, heavy neck and neck, and easy to fall when walking for no reason. These symptoms are generally lighter in the early morning, aggravated by activity and fatigue, and improve after rest. In addition to transverse muscle weakness, there are also visceral manifestations, which can cause the patient to lose labor force or even die.